Avutometinib, Defactinib, and Letrozole for Low-Grade Ovarian Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have low-grade serous ovarian, fallopian tube, or primary peritoneal cancer (confirmed by a biopsy).
- You cannot have received any previous chemotherapy, hormone therapy, or other systemic treatment for this cancer.
- Your cancer must be measurable on a CT or MRI scan (at least one tumor that is 10 mm or larger, or a lymph node 15 mm or larger).
- You must be healthy enough to care for yourself (ECOG performance status 0–1), or up to 2 if your health issues are solely from the cancer.
- You must have adequate organ function (kidney, liver, blood counts, and heart function) as tested by standard lab work and imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
This trial lets people who are already doing well on a study treatment keep receiving it. It tests whether continuing the combination of avutometinib and defactinib remains safe and helpful for recurrent low-grade serous ovarian cancer.
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Hear when a new Low Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.